A three-drug combination targeting aggressive advanced breast cancer could potentially double the amount ... but was given ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

(RTTNews) - IceCure Medical Ltd. (ICCM), Friday announced that the U.S. Food and Drug Administration's Advisory panel has voted in favor of the company's ProSense technology intended for early-stage ...

The test identifies patients for targeted therapies in breast, colorectal ... may benefit from treatment with targeted therapies. MI Cancer Seek™ has received approval from the Food and Drug ...

A powerful, three-drug therapy for aggressive advanced breast cancer doubles the length of time before the cancer progresses, ...

A three-drug combination targeting aggressive advanced breast cancer could potentially ... but was given the green light by the USA’s Food and Drug Administration (FDA) earlier this month.

The FDA continues to approve new drugs and expand indications for others at a rapid pace. Here’s a summary of what happened ...

The U.S. Food and Drug Administration has approved Itovebi ... locally advanced or metastatic breast cancer. The approval is for the PIK3CA mutation, one of the most commonly mutated genes ...

Six/UW/Seattle Children’s Cancer Consortium scientists received new funding from the Breast Cancer Research Foundation to ...

Huge breakthrough’ in breast cancer drug therapy ‘doubles survival time’ - New three drug combination could be ...

A three-drug therapy targeting breast cancer could double the amount of time patients live without the disease progressing, a trial has found. Researchers praised the “huge breakthrough” as ...